Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pasithea Therapeutics Equity Warrant Exp 11th Aug 2026 KTTAW

Healthcare Biotechnology
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small... see more

Recent & Breaking News (NDAQ:KTTAW)

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

GlobeNewswire 1 day ago

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

GlobeNewswire February 13, 2024

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

GlobeNewswire January 8, 2024

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

GlobeNewswire January 2, 2024

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

GlobeNewswire December 28, 2023

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

GlobeNewswire December 19, 2023

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

GlobeNewswire December 11, 2023

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

GlobeNewswire November 29, 2023

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

GlobeNewswire November 29, 2023

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

GlobeNewswire November 9, 2023

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

GlobeNewswire September 14, 2023

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 7, 2023

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function

GlobeNewswire August 1, 2023

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

GlobeNewswire July 20, 2023

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

GlobeNewswire July 20, 2023

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

GlobeNewswire June 30, 2023

Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004

GlobeNewswire June 29, 2023

Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.

GlobeNewswire June 6, 2023

Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference

GlobeNewswire June 1, 2023

Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference

GlobeNewswire May 3, 2023